Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Closed 03-27 16:00:00 EDT

84.61

-3.49

-3.96%

盘后84.61

+0.000.00%

19:50 EDT

High88.41	Low83.45	Vol2.16M
Open87.24	D1 Closing88.10	Amplitude5.63%
Mkt Cap11.10B	Tradable Cap10.66B	Total Shares131.17M
T/O183.34M	T/O Rate1.71%	Tradable Shares126.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":84.61,"timestamp":1774641600000,"preClose":88.1,"halted":0,"volume":2156800,"hourTrading":{"tag":"盘后","latestPrice":84.61,"preClose":84.61,"latestTime":"19:50 EDT","volume":42897,"amount":3629516.15,"timestamp":1774655413422,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03961407491486941,"floatShares":126000000,"shares":131170441,"eps":-3.320281,"marketStatus":"Closed","change":-3.49,"latestTime":"03-27 16:00:00 EDT","open":87.24,"high":88.41,"low":83.45,"amount":183344965.38880002,"amplitude":0.0563,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.320281,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":88.1,"preHourTrading":{"tag":"盘前","latestPrice":87.45,"preClose":88.1,"latestTime":"08:04 EDT","volume":84,"amount":7346.36448,"timestamp":1774613061663,"change":-0.65,"changeRate":-0.007378,"amplitude":0.006924},"postHourTrading":{"tag":"盘后","latestPrice":84.61,"preClose":84.61,"latestTime":"19:50 EDT","volume":42897,"amount":3629516.15,"timestamp":1774655413422,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.144705,"impliedVol":0.6761,"impliedVolPercentile":0.7649},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"2622689008","title":"GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689008?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:49","pubTimestamp":1774453776,"startTime":"0","endTime":"0","summary":"An announcement from GH Research ( ($GHRS) ) is now available. On March 25, 2026, GH Research PLC reported that full results from its randomized, d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-publishes-phase-2b-gh001-trd-data-and-highlights-severity-independent-efficacy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-publishes-phase-2b-gh001-trd-data-and-highlights-severity-independent-efficacy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4585","BK4535","BK4588","BK4551","BK4196"],"gpt_icon":0},{"id":"2622070560","title":"GH Research announces publication of Phase 2b results for mebufotenin","url":"https://stock-news.laohu8.com/highlight/detail?id=2622070560","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622070560?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:15","pubTimestamp":1774451716,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression: the prim...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-announces-publication-of-phase-2b-results-for-mebufotenin-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4551","BK4196","BK4585","GHRS","BK4535","BK4007","BK4539","GH"],"gpt_icon":0},{"id":"2622077031","title":"GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077031","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077031?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:10","pubTimestamp":1774451400,"startTime":"0","endTime":"0","summary":"Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262385/0/en/GH-Research-Announces-Publication-of-Phase-2b-Results-for-Mebufotenin-GH001-in-JAMA-Psychiatry-and-Reports-New-Finding-of-Severity-Independent-Efficacy-in-TRD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4535","BK4196","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2621983800","title":"Guardant Health, Verana Health announce new partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2621983800","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621983800?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:20","pubTimestamp":1774358446,"startTime":"0","endTime":"0","summary":"Verana Health has announced a new partnership with Guardant Health (GH) that will allow biopharmaceutical researchers to access the combined resour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-verana-health-announce-new-partnership-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-verana-health-announce-new-partnership-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4535","BK4196","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2621606054","title":"Verana Health and Guardant Health partner to combine EHR and clinicogenomic data for oncology research","url":"https://stock-news.laohu8.com/highlight/detail?id=2621606054","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621606054?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:15","pubTimestamp":1774358128,"startTime":"0","endTime":"0","summary":"Guardant Health and Verana Health entered a partnership to combine Verana’s curated EHR datasets with Guardant’s clinicogenomic testing data for biopharmaceutical research.The collaboration is intended to support analyses of relationships between molecular biomarkers, treatment decisions, and clinical outcomes using longitudinal real-world data.Guardant’s datasets include serial testing across disease stages, while Verana’s data covers patient care journeys from academic and community care settings.The combined data assets are expected to expand Verana’s coverage of solid tumors, including lung, breast, and colorectal cancers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL4tCpmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4551","BK4196","BK4585","BK4535","GH"],"gpt_icon":0},{"id":"2621276867","title":"Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2621276867","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621276867?lang=en_us&edition=fundamental","pubTime":"2026-03-23 13:04","pubTimestamp":1774242294,"startTime":"0","endTime":"0","summary":"Shield launch in Asia puts Guardant Health in focus\nGuardant Health (GH) is in the spotlight after announcing a partnership with Manulife to offer its Shield multi cancer detection blood test to eligible customers in Hong Kong, Singapore and the Philippines starting in April 2026.\nSee our latest analysis for Guardant Health.\nDespite the Shield news, Guardant Health’s 1-day share price return of a 4.38% decline and 30-day share price return of a 17.38% decline sit alongside a 1-year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MFC","BK4551","LU1989771016.USD","BK4588","BK4196","BK4162","GH","LU1291159041.SGD","BK4535","BK4585"],"gpt_icon":0},{"id":"2620714252","title":"Guardant Health director Tariq Musa reports disposal of USD 30,660 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620714252","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620714252?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:16","pubTimestamp":1773955008,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa reported a sale of 348 common shares on 03/18/2026 at USD 88.09 per share.Following the transaction, Musa beneficially owned 8,394 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbSSZ0R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Tariq Musa reports disposal of USD 30,660 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4196","GH","BK4551","BK4535"],"gpt_icon":0},{"id":"2620253577","title":"Guardant Health to present 28 abstracts at AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253577","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253577?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:06","pubTimestamp":1773835605,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLlSsG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4551","BK4535","GH","BK4196"],"gpt_icon":0},{"id":"2620409920","title":"Guardant Health CFO Michael Brian Bell disposes of USD 261,111 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620409920","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620409920?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:46","pubTimestamp":1773787610,"startTime":"0","endTime":"0","summary":"Michael Brian Bell, chief financial officer of Guardant Health, reported a disposal of common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4gHNmh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CFO Michael Brian Bell disposes of USD 261,111 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4196","GH","BK4585","BK4535"],"gpt_icon":0},{"id":"2619746310","title":"Bitdeer Launches SEALMINER DL1 Air: Achieving 149 J/GH Power Efficiency and 25 GH/s for Scrypt Mining","url":"https://stock-news.laohu8.com/highlight/detail?id=2619746310","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619746310?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:30","pubTimestamp":1773664200,"startTime":"0","endTime":"0","summary":"SINGAPORE, March  16, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, toda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256284/0/en/Bitdeer-Launches-SEALMINER-DL1-Air-Achieving-149-J-GH-Power-Efficiency-and-25-GH-s-for-Scrypt-Mining.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4203","LU0320765646.SGD","LU0234572021.USD","BTDR","GH","LTC","LU1244550577.SGD","IE00BBT3K403.USD","BK4234","BK4084","PEP","LU1244550494.USD","IE00BLSP4239.USD","BK4534","IE00BLSP4452.SGD","BK4533","BK4177","BK4225","BK4581","BK4600","BK4550","LU1244550221.USD","BK4585","IE00B3T34201.USD","IE00BN8TJ469.HKD","BK4535","BK4196","LU0098860793.USD","BK4504","BK4588","PW","LU1162221912.USD","BK4566","LU1894683264.USD","LU1929549753.HKD","LU1894683348.USD","BK4595","BK4551"],"gpt_icon":0},{"id":"2619468258","title":"BRIEF-Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468258","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468258?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:20","pubTimestamp":1773663619,"startTime":"0","endTime":"0","summary":"BRIEF-Guardant Health Launches Shield Multi-Cancer Detection (Mcd) Test In Multiple Markets In Asia With Manulife PartnershipMarch 16 (Reuters) - Guardant Health Inc GH.O:GUARDANT HEALTH LAUNCHES SHIE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA9BHYZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","GH","BK4535","BK4196","BK4551"],"gpt_icon":0},{"id":"2619468978","title":"Guardant Health Inc - Manulife Customers in Asia to Access Shield Mcd Test Beginning April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468978?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:05","pubTimestamp":1773662700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA9BHYZS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4588","BK4535","GH","BK4196","BK4585"],"gpt_icon":0},{"id":"2619843231","title":"Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619843231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619843231?lang=en_us&edition=fundamental","pubTime":"2026-03-16 14:12","pubTimestamp":1773641534,"startTime":"0","endTime":"0","summary":"Earlier this month, Guardant Health launched Shield Across America, a coast-to-coast mobile tour bringing its FDA-approved Shield blood test for primary colorectal cancer screening directly to more than 100 communities, with a focus on underserved rural areas and screening-eligible adults.\nBy combining this outreach with strong survey support for blood-based screening, updated National Comprehensive Cancer Network guidelines, and broad public payer coverage, Guardant is working to reduce...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/is-guardant-healths-gh-shield-tour-redefining-its-competitiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4588","GH","BK4196","BK4585","BK4551"],"gpt_icon":0},{"id":"2619438111","title":"Manulife Announces Exclusive Partnership With Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2619438111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619438111?lang=en_us&edition=fundamental","pubTime":"2026-03-16 11:00","pubTimestamp":1773630002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA97JSX3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GH","BK4535","BK4196","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2619194223","title":"Guardant Health survey shows 92% support no-copay coverage for colorectal cancer blood tests","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194223","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194223?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:09","pubTimestamp":1773403746,"startTime":"0","endTime":"0","summary":"Guardant reported results from a Harris Poll survey of 1,189 U.S. adults aged 45 and older on colorectal cancer screening. The survey found that 92% of screening-eligible adults said blood-based colorectal cancer screening should be covered with no co-pay similar to Medicare Part B and VA Community Care. It also found that 71% said they have felt or would feel anxious before having a colonoscopy, and 77% said they would be less likely to avoid or delay screening if an FDA-approved blood test option were available. Guardant said 85% reported they would be more likely to get a colonoscopy after a positive blood-based screening result, and 54% said stool-based tests “gross them out.” The company also reported a 93% adherence rate in the first 100,000 Shield tests ordered.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL6Mpsrx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4585","BK4551","BK4588","GH","BK4535"],"gpt_icon":0},{"id":"2618614943","title":"Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2618614943","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618614943?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:00","pubTimestamp":1773223200,"startTime":"0","endTime":"0","summary":"Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last yearBraidwell generated 28% gross return in 2025Braidwell's investments include Guardant Health, Alphatec, and Caris Life SciencesFi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL6N3ZL1C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","BK4543","BK4602","GH","ATEC","LU0868494617.USD","LU1880398471.USD","BK4612","BK4585","BK4534","LU1894683348.USD","LU1559883803.SGD","BK4082","LU1585245621.USD","BK4588","BK4535","BK4196","BK4575","BK4139","BK4104","BK4538","BK4533","LU0321505868.SGD","LU1778281490.HKD","LU0566484027.USD","LU1883839398.USD","LU0321505439.SGD","LU1674673691.USD","BK4134","LU1430594728.SGD","LU1674673428.USD","LU1880398554.USD","IBM","BK4551","BK4579","CAI"],"gpt_icon":0},{"id":"2618934984","title":"GH Research price target raised to $34 from $29 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934984?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:01","pubTimestamp":1773140494,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Eddie Hickman raised the firm’s price target on GH Research (GHRS) to $34 from $29 and keeps a Buy rating on the shares after th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-34-from-29-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-34-from-29-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"gpt_icon":0},{"id":"2617204659","title":"Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617204659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617204659?lang=en_us&edition=fundamental","pubTime":"2026-03-07 09:50","pubTimestamp":1772848211,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GH Research (GHRS – Research Report) and Sionna Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-sionna-therapeutics-inc-sion-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-sionna-therapeutics-inc-sion-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GHRS","BK4007","HCSG","BK4196","BK4551","XBI","BK4585","GH","BK4137","BK4539","BK4139","LU0029874061.USD","BK4588","LABU","SION","BK4535","LU0128526141.USD","BK4581","XLV"],"gpt_icon":0},{"id":"2617687951","title":"GH Research Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687951","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617687951?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:19","pubTimestamp":1772799540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 07:19 ET (12:19 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2617097682","title":"Stifel Nicolaus Sticks to Their Buy Rating for GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617097682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617097682?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:58","pubTimestamp":1772798311,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst reiterated a Buy rating on GH Research today and set a price target of $32.00. In a report released today, Citizens JMP als...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","GHRS","SF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0765},{"period":"3month","weight":-0.1445},{"period":"6month","weight":0.4676},{"period":"1year","weight":0.9219},{"period":"ytd","weight":-0.1375}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.028493},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.017651},{"month":5,"riseRate":0.571429,"avgChangeRate":0.065461},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction